New Healthcare Analyst Report: Breaching the Blood-Brain Barrier - CNS Therapeutic Development

The blood-brain barrier (BBB) presents a significant challenge in developing effective treatments for central nervous system disorders. Various approaches are being explored to overcome this pharmacological challenge, including shuttle technologies, viral vectors, non-viral delivery particles, intranasal distribution, and devices for direct delivery to the CNS.

Biopharma companies and investors have shown significant interest in BBB technologies, with 63 strategic transactions (licensing/acquisitions) over the past six years and USD2.5bn raised in total from venture financing between 2019 and 2023. 

The DNB//Back Bay Partnership analyzed the clinical development landscape, recent transactions, and financing activity to better understand which technologies are advancing to the clinic and gaining traction.

 Learn about DNB//Back Bay and read our disclosures: www.bblsa.com/dnbback-bay